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methylthioadenosine is a prognostic biomarker and an
inflammatory regulator in sepsis
Liuyang Wang,1 Emily R. Ko,2,3 James J. Gilchrist,4,5 Kelly J. Pittman,1 Anna Rautanen,4
Matti Pirinen,4 J. Will Thompson,6 Laura G. Dubois,6 Raymond J. Langley,7 Sarah L. Jaslow,1
Raul E. Salinas,1 D. Clayburn Rouse,8 M. Arthur Moseley,3,6 Salim Mwarumba,9 Patricia Njuguna,9
Neema Mturi,9 Wellcome Trust Case Control Consortium 2,† Kenyan Bacteraemia Study Group,†
Thomas N. Williams,9,10 J. Anthony G. Scott,9,11 Adrian V. S. Hill,4,12 Christopher W. Woods,3,13,14
Geoffrey S. Ginsburg,3 Ephraim L. Tsalik,3,13,15 Dennis C. Ko1,13*Sepsis is a deleterious inflammatory response to infection with high mortality. Reliable sepsis biomarkers could im-
prove diagnosis, prognosis, and treatment. Integration of human genetics, patient metabolite and cytokine measure-
ments, and testing in a mouse model demonstrate that the methionine salvage pathway is a regulator of sepsis that
can accurately predict prognosis in patients. Pathway-based genome-wide association analysis of nontyphoidal
Salmonella bacteremia showed a strong enrichment for single-nucleotide polymorphisms near the components of
the methionine salvage pathway. Measurement of the pathway’s substrate, methylthioadenosine (MTA), in two
cohorts of sepsis patients demonstrated increased plasma MTA in nonsurvivors. Plasma MTA was correlated with
levels of inflammatory cytokines, indicating that elevated MTA marks a subset of patients with excessive inflam-
mation. Amachine-learningmodel combiningMTA and other variables yielded approximately 80% accuracy (area
under the curve) in predicting death. Furthermore, mice infected with Salmonella had prolonged survival when
MTA was administered before infection, suggesting that manipulating MTA levels could regulate the severity of
the inflammatory response. Our results demonstrate how combining genetic data, biomolecule measurements,
and animal models can shape our understanding of disease and lead to new biomarkers for patient stratification
and potential therapeutic targeting.INTRODUCTION
The 20th century witnessed a remarkable decrease in infectious disease
deaths. Although a great deal of the decline was due to improved san-
itation (1), early antibiotics, resuscitation, and supportive hospital care
have also playedmajor roles, particularly in improving outcomes in bac-
teremia and sepsis (2, 3). With sepsis mortality rates up to 30% even in
advanced care settings (4, 5), there has long been hope that this thera-
peutic arsenal could be complemented by host-directed sepsis therapies.
However, failures in more than 100 clinical trials aimed at modulating
the immune response in sepsis have demonstrated that a better
understanding of host biology and differences in clinical factors is nec-essary (6). Heterogeneous host responses to infection, some on opposite
ends of an inflammatory spectrum (7), havemade progress difficult. It is
unclear whether these failed clinical trials can be more accurately
attributed to a failure of the treatments or to a failure in the diagnostic
criteria. Most recently, the Sepsis Definitions Task Force has updated
definitions for sepsis and septic shock, underscoring the importance
of sepsis criteria for clinical trials ofmolecular therapies (8–10). Notably,
the new definitions remain broad in their criteria, encompassing a wide
variety of patients with varying etiology and pathophysiology. There-
fore, an important goal toward personalized treatment is to improve
stratification of patients for clinical trials by developing better biomar-
kers and integrating information on clinical course, site of infection,
cellular dysfunction, and other factors (11).Metabolitemarkers are par-
ticularly attractive for this goal because they serve to integrate multiple
inputs (transcriptional, translational, and environmental) into an active
biomolecule that can have large effects on physiology. On the other
hand, genetic markers of susceptibility have the advantage of not
changing during the course of disease,making the direction of causation
for true genetic associations unambiguous. Therefore, an improved
understanding of human genetic differences that contribute to regula-
tion ofmetabolite levels could powerfully couple the larger effect sizes of
metabolites to the causality of genetic variants for prioritizing and
designing interventions.
One component of the host response that has received significant
interest in characterizing and possibly treating sepsis is the activation of
inflammatory caspases (12, 13). A variety of bacterial patterns and danger
signals can trigger the formation of molecular scaffolds called inflam-
masomes that serve to activate the inflammatory caspases (caspase-1,
caspase-4, and caspase-5 in humans and caspase-1 and caspase-11 in1 of 14
SC I ENCE ADVANCES | R E S EARCH ART I C L Emice) (14–16). The two best characterized effects of this activation are
secretion of cleaved/activated forms of interleukin-1b (IL-1b) and
IL-18 and induction of a proinflammatory form of cell death known
as pyroptosis. In addition to releasing proinflammatory cellular compo-
nents, pyroptosis likely also serves as ameans of depriving somebacteria
of their intracellular niche (17). Targeting some of these downstream
effects of inflammatory caspases has previously been examined for sep-
sis therapy. In clinical trials, IL-1 receptor antagonist (IL-1ra) showed a
small but significant improvement in 28-day survival time for a select
group of patients presenting with severe sepsis without shock (18), but a
subsequent multicenter trial could not recapitulate these results (19). A
synonymous coding variant in IL-1ra that leads to increased plasma
levels of the protein was associated with improved survival from septic
shock, further suggesting thatmodulation of the inflammatory response
by IL-1ramay benefit select patients (20). In regard to the secondmajor
function of caspase activation, inhibition of cell death has shown benefit
in some animal sepsis models (21, 22), but the relevance of pyroptosis
during sepsis in humans remains poorly understood.
Here, we have developed a hypothesis from the discovery of natu-
rally occurring genetic variation modulating pyroptosis (23, 24) and
tested it in multiple patient data sets. Specifically, we previously
determined that a single-nucleotide polymorphism (SNP) associated
with the expression level of the APIP gene was associated with both
Salmonella-induced pyroptosis in vitro and bacteremia and risk of death
in patients with the systemic inflammatory response syndrome (SIRS)
(25). BecauseAPIP encodes amethionine salvage enzyme and regulates
the levels of the substrate of the pathway, methylthioadenosine (MTA)
(25–27), one hypothesis is that MTA could serve as a rheostat for inflam-
matory response that could modulate susceptibility and severity of sepsis
(28). Although other studies have demonstrated an anti-inflammatory
effect ofMTA in lipopolysaccharide (LPS) endotoxemia (29) and in chem-
ically induced colitis (30), our previous work suggests a proinflammatory
activity during infection because exogenous MTA increased Salmonella-
induced pyroptosis in cultured cells (25). Thus, there is controversy
surrounding the role of MTA in inflammation. Furthermore, how MTA
levels change during the course of infection and its possible value as a bio-
marker in sepsis have never before been examined.
In this study, we have confirmed that APIP is associated with bacte-
remia using a nontyphoidal Salmonella (NTS) bacteremia data set from
Kenya (31). We also have found a clear enrichment of bacteremia-asso-
ciated SNPs near components of the methionine salvage pathway, impli-
cating, for the first time, the entire methionine salvage pathway as a
regulator of bacteremia and sepsis. We then used samples from two pro-
spective clinical studies to examine the relationships among APIP, MTA
levels, and sepsis outcome. We discovered that elevated plasma MTA
levels near the time of suspected infection are associatedwith death in sep-
sis and that measurement of this single metabolite provides prognostic
ability comparable to the frequently used APACHE II (Acute Physiology
and Chronic Health Evaluation II) score (32); however, unlike APACHE
II, elevated MTA levels are specific to infection. A mouse model of
Salmonella infection mirrored the elevated plasma levels of MTA ob-
served in humans. Furthermore, we found that tissue MTA levels in
mice were depleted during infection, lending insight into the direction-
ality of the MTA response. Finally, administration of exogenous MTA
to mice before infection prolonged survival and suppressed levels of
proinflammatory cytokines. Our study shows that the methionine sal-
vage pathway is an important metabolic regulator of sepsis and that
MTA could be used as a powerful prognostic biomarker with potential
therapeutic benefit in sepsis.Wang et al., Sci. Adv. 2017;3 : e1602096 8 March 2017RESULTS
SNPs in the methionine salvage pathway are associated with
NTS bacteremia
We previously showed that natural genetic variation affecting APIP
gene expression could regulate the susceptibility of cells to undergo a
form of proinflammatory cell death called pyroptosis, triggered by
Salmonella and other infections. This effect on pyroptosis wasmediated
by the role of APIP in themethionine salvage pathway. In patients from
Seattle hospitals meeting the physiologic criteria for SIRS, the allele as-
sociated with reduced expression of APIP was associated with reduced
odds of culture-verified sepsis and reduced odds of death (25).However,
it remained unclear whether association with the lower-expressed,
proinflammatoryAPIP allele was specific to infection or a more general
indicator of a severe inflammatory response from both infectious and
noninfectious causes. To further explore the relationship with infection
in human cohorts, we examined genome-wide association study
(GWAS) data performed in 180 Kenyan children with blood culture–
positive (bacteremia) NTS infection and 2677 controls from a birth co-
hort of the same population (31) to determine whether SNPs in/near
APIP demonstrated an associationwith this specific diagnosis. All studies
used in this study are summarized in Table 1.
We observed an association signal near the APIP gene with NTS
bacteremia (Fig. 1A). The strongest association was seen with the non-
coding SNP rs2433162 [P = 4.8 × 10−7; odds ratio (OR) = 0.43, domi-
nant model], but there was also an association, albeit weaker, with
rs514182 (P = 0.03; OR = 0.71, dominant model). The rs514182 SNP
is the same SNP associated with reduced expression levels of APIP and
increased pyroptosis in the cell culture model (25). The directionality of
effect seen in the current study was consistent with the findings of our
previous patient studies: The proinflammatory allele of APIP is asso-
ciated with reduced odds of bacteremia and death in SIRS patients in
Seattle (25) and with reduced odds of NTS bacteremia in Kenya.
The association of theAPIP SNPswithNTSbacteremia confirms the
role of this gene in the regulation of bacteremia and sepsis. However,
these results do not show whether this effect is mediated through the
role of APIP in the methionine salvage pathway. APIP has been re-
ported to have distinct roles in two cell death pathways, pyroptosis
and apoptosis. We previously have shown (25) and others have con-
firmed (26) that, although the enzymatic methionine salvage activity
is required for regulation of pyroptosis, regulation of apoptosis is due
to a different domain of the protein.
If methionine salvage is the mechanism by which APIP regulates
sepsis, thenwewould predict that other genetic variants near or in genes
encoding enzymes in the methionine salvage pathwaymight also be as-
sociated with NTS bacteremia. Pathway analysis using INRICH (33)
showed that the only pathway showing significant enrichment in the
NTS bacteremia GWAS was “metabolism of polyamines” (empirical
P = 2.0 × 10−5, P = 0.01 after multiple-test correction). Three of the in-
dividual GWAS signals identified by this pathway-based analysis are
from components of the methionine salvage pathway (half of the six
enzymes that make up the pathway), while a fourth is part of the poly-
amine synthesis pathway, which results in MTA production (Fig. 1, B
and C). The findings strongly implicate the methionine salvage
pathway in defense against NTS infection. Although each SNP
contributes a small fraction to overall genetic risk for bacteremia,
we hypothesized that the metabolite that feeds into the pathway
(MTA) could be playing a central regulatory role, larger than the role
of the individual SNPs (Fig. 1D). Therefore, we characterized the role
of MTA in sepsis patients.2 of 14
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To determine whether there was an association between MTA levels
and sepsis outcomes, we used plasma samples that had previously un-
dergone metabolomics profiling as part of the Community Acquired
Pneumonia and Sepsis Outcome Diagnostics (CAPSOD) study (34–36).
Briefly, 1152 patients with suspected community-acquired infection
and who met SIRS criteria were enrolled in the emergency rooms of
three U.S. hospitals, and extensive phenotypic and laboratory data were
collected. Some were later adjudicated as having noninfectious SIRS,
allowing grouping based on etiology (noninfectious SIRS versus sepsis)
and by primary outcome (survival versus death). A 121-subject subset
with sepsis previously underwentmetabolomics profiling (Table 2) (34).
Our subsequent evaluation of the MTA levels in these CAPSOD
samples demonstrated an association between relative MTA levels
and sepsis outcome (Fig. 2A, P = 0.002). Sepsis survivors had signifi-
cantly lower levels of MTA compared to the sepsis nonsurvivors.
Although we had hypothesized that an association would be present
based on the genetic data, what was unexpected was the direction of
effect. Because the low–APIP expression allele (presumably resulting
in higher steady-state MTA) is associated with a decreased odds of bac-
teremia and death in SIRS patients (25) and decreased odds of NTS bac-
teremia, we had anticipated that higher MTA would also be protective
against infection. The fact that higher plasmaMTAwas associated with
death prompted us to explore two possible explanations: (i) that thereWang et al., Sci. Adv. 2017;3 : e1602096 8 March 2017might be temporal variation inMTA levels during infection (theCAPSOD
study has no information regarding when the suspected infection
occurred relative to the measurement of MTA) or (ii) that changes in
extracellular (plasma) MTA levels measured on patient samples might
not reflect intracellular changes important for response to infection.
Response to infection may require differential regulation of inflam-
mation during the course of infection. For example, a proinflammatory
response may be beneficial early during infection, allowing a stronger
bactericidal effect, whereas reduction of the inflammatory response later
in infection may be beneficial to prevent tissue injury. To test for repli-
cation of the association of MTA level with sepsis outcome and to de-
termine how this association changed during the progression of sepsis,
we used patient samples collected as part of a prospective study on hos-
pitalized patients (Table 2). This study was originally designed to eval-
uate the risk of health care–associated infections (HAIs) with a focus on
ventilator-associated pneumonia (VAP) (HAI-VAP study).
Patients admitted to the hospital for noninfectious reasons (for ex-
ample, after surgery, trauma, stroke, or cardiac arrest) who were at risk
for HAI by virtue of intubation were enrolled into the study and
monitored for the development of infection, and blood samples were
obtained serially. Patients who had multiple time points and onset of
HAI during the observation and sampling period were selected for
MTA analysis. This study design not only allowed validation of the
MTA association with sepsis outcome found in the CAPSOD cohortTable 1. Summary of patient populations used in this work. ICU, intensive care unit; UNC, University of North Carolina.Study Patient population Cases Controls MeasurementsMajor finding
regarding
methionine
salvage
First reference
on patient
cohortSeattle SIRSAdult ICU patients in
Harborview Medical Center
(Seattle, WA) meeting at least
three of four SIRS criteria(i) SIRS
nonsurvivors
(n = 128)(i) SIRS
survivors
(n = 776)
Genotyping
for APIP
APIP genotype associated
with
SIRS death (25)(25)(ii) Culture-
positive sepsis
(n = 149)
n
(ii) Culture-
egative SIRS
(n = 755)
Genotyping
for APIP
APIP genotype
associated with
culture-verified
sepsis (25)Kenyan bacteremia Children in the Kilifi DistrictHospital (Kilifi, Kenya)
NTS bacteremia
(n = 180)Birth cohort
population
controls
(n = 2677)
Genotyping on
Affymetrix array
6.0 for GWAS
and pathway
enrichment
APIP genotype associated
with NTS bacteremia
(this study) (31)Enrichment of SNPs
in the methionine
salvage pathway with
NTS bacteremia (this
study)CAPSODEmergency room patients in the
Henry Ford Hospital (Detroit, MI),
the Duke University Medical Center
(Durham, NC), and the Durham Veteran
Affairs Medical Center (Durham, NC)
meeting at least two of four SIRS
criteria and with suspected infectionSepsis
nonsurvivors
(n = 31)Sepsis
survivors
(n = 90)
Metabolomics
including MTA
measurement
MTA is associated with
death in sepsis
patients (this study)(34)HAI-VAPAdult patients in the Duke University
Medical Center (Durham, NC),
the Durham VA Medical Center
(Durham, NC), and the UNC
Medical Center (Chapel Hill, NC)
at high risk of health care–associated
infection
(
nSepsis
nonsurvivors
n = 37 samples;
= 16 patients)Sepsis
survivors
(n = 68
samples;
n = 20
patients)
MTA
measurement
MTA is associated
with death in
sepsis patients
(this study)This study3 of 14
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and after sepsis onset.
In the HAI-VAP study, elevated MTA was associated with sepsis
nonsurvival, and the association was strongest soon after the time of
suspected infection (Fig. 2B; P = 0.03 at 0 to 1 day and P = 0.01 at 2
to 3 days after apparent onset of infection). These associations remained
significant after controlling for age and sex (P = 0.03 at 0 to 1 day after
suspected infection). At later time points, the association was no longer
observed (Fig. 2B; P = 0.6 at 4 to 8 days after suspected infection). We
were unable to draw conclusions about the prognostic value of MTA
levels before infection because of an insufficient number of samplesWang et al., Sci. Adv. 2017;3 : e1602096 8 March 2017collected before infection for patients in the nonsurvivor group. The as-
sociation was specific only to the sepsis patients; no association was
found betweenMTA levels and death in the uninfected control patients
(Fig. 2B). Furthermore, no difference inMTA levels was observed in the
VAP samples comparing overall sepsis versus noninfectious SIRS
(fig. S1).
In the same mass spectrometry assay used for measuring MTA (see
Materials and Methods), we also measured related metabolites [me-
thionine, S-adenosyl homocysteine (SAH), and S-adenosyl methio-
nine (SAM)], several amino acids (Leu, Ile, Phe, and Arg), and the
polyamine spermine. As might be expected on the basis of theirFig. 1. SNPs nearmethionine salvage genes are associatedwith NTS bacteremia. (A) Association plot of NTS bacteremia susceptibility in the APIP region. Imputed SNPs are
plotted as circles, and directly genotyped SNPs are plotted as diamonds. SNPs are colored according to strength of linkage disequilibrium (r2) to rs2433162. Association statistics
are calculated with a dominant model (the most likely model of association at rs2433162). (B) Methionine metabolism schematic with genes listed for each enzymatic step and
structures for three major metabolites. The four genes implicated with pathway enrichment analysis for NTS bacteremia GWAS are in red boldface. (C) Association plots of the
three regions (in addition toAPIP) associatedwithNTS bacteremia and involved inmethionine salvage: ENOPH1,MTAP, andAMD1. Imputed SNPs are plotted as circles, and directly
genotyped SNPs are plotted as diamonds. SNPs are colored according to strength of linkage disequilibrium (r2) to the lead SNP. Association statistics are calculatedwith themodel
of association observed for the lead SNP in each region (ENOPH1, recessive; MTAP, recessive; AMD1, dominant). (D) Model for how the SNPs nearmethionine salvage genes could
affect sepsis. MTA may integrate genetic variation and other inputs to serve as a sepsis biomarker.4 of 14
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lites by patient profiles suggested coregulation ofMTA, SAH, and SAM
(Fig. 2C). Although SAH and SAM approached significance (P = 0.05
and P = 0.06, respectively), none of the other metabolites examined
showed a statistically significant association with sepsis survival (Table 3).
Thus, we have demonstrated that high MTA levels in plasma are asso-
ciated with increased mortality in sepsis patients in two independent
cohorts and that the association is strongest within 3 days of suspected
infection.
Lethal NTS infection of mice decreased MTA levels in tissues
but increased levels in plasma
Measurement of MTA levels in the HAI-VAP study confirmed the as-
sociation between MTA levels and sepsis death seen in the CAPSOD
samples and demonstrated the timing of this response. However, the
increased temporal resolution of the HAI-VAP cohort did not reveal
why the direction of effect was opposite of what was predicted from
theAPIP genetic association. Therefore, we turned to amouse Salmonella
infectionmodel to determine how tissue levels ofMTAdiffered in com-
parison to plasma levels.
Mice underwent intraperitoneal infection with Salmonella Typhi-
murium at a dosage (1 × 106) that usually results in death in 1 to 4 days
(Fig. 3A). PlasmaMTA levels spiked at 6 hours after infection but then
returned largely to normal values by 24 hours (Fig. 3B). This is
consistent with the high levels of plasma MTA seen near the time of
infection in the sepsis nonsurvival cohort of the HAI-VAP study. How-
ever,MTA levels in the spleen showed the opposite relationship at 6 hours.Wang et al., Sci. Adv. 2017;3 : e1602096 8 March 2017MTA levels were markedly decreased and then showed a trend toward
returning to normal by 24 hours (Fig. 3, C andD). A similar decline was
noted in the liver, although the decrease was still apparent at 24 hours
(Fig. 3D). Therefore, although plasmaMTA levels are increased in severe
bacterial infection, there is actually a drop in tissue MTA levels. These
opposite changes in tissue and plasmaMTA levels provide one plausible
explanation for why a higher mortality could be associated with both
higher plasma levels of MTA in the CAPSOD and HAI-VAP cohorts
and the APIP SNP allele predicted to result in lower intracellular MTA
levels in the Seattle SIRS cohort (25); the reduction in tissuesmight be the
source for the increase in plasma during infection. Future studies of
human sepsis tissues or peripheral blood mononuclear cells will be
necessary to test the model that a reduction of MTA in tissues is ac-
companied by a rise in plasma levels of MTA early in the temporal
course of infection and associated with worse outcome in sepsis.
MTA is a prognostic biomarker for death in sepsis
The strong association between MTA and sepsis survival prompted us
to evaluate the utility ofMTAas a prognostic biomarker.We found that,
in theCAPSODcohort,MTAhadmoderate prognostic power [receiver
operating characteristic (ROC) curve with area under the curve (AUC),
0.69; 95% confidence interval (CI), 0.59 to 0.80; Fig. 4A]. However, we
suspected that the power might be improved if the time relative to
suspected infection were known. In the HAI-VAP study, plasma
MTA levels at the time of suspected infection and soon after had improved
predictive power [ROCcurveswithAUC, 0.74 (95%CI, 0.55 to 0.93) for
0 to 1 day, 0.79 (95% CI, 0.61 to 0.98) for 2 to 3 days, and 0.60 (95% CI,Table 2. Clinical variables and demographics for VAP and CAPSOD patient cohorts. Data are presented as means ± SD. NI-SIRS, noninfectious SIRS; B/W/O,
black, white, other; BMI, body mass index.Clinical variable
CAPSOD sepsis metabolomics cohort VAP cohortSepsis survivors Sepsis nonsurvivors NI-SIRS survivors NI-SIRS nonsurvivors Sepsis survivors Sepsis nonsurvivorsNo. of samples 40 12 68 37No. of patients 90 31 20 6 20 16Age (years) 56.4 ± 19.2 68.8 ± 16.7 55 ± 17.3 61.5 ± 20.2 52 ± 21.5 58 ± 16.7Gender (% male) 58.9 54.8 100.0 83.3 82.4 67.6Race (B/W/O) 56/28/6 23/7/1 6/13/1 2/4/0 8/10*/1 2/14/0APACHE II 15.0 ± 7.1 22.8 ± 7.8 17 ± 9.6 18.5 ± 8.8 17 ± 4.9 22 ± 10.2BMI — — 32 ± 10.8 25 ± 4.0 27.5 ± 5.1 29 ± 5.2Tube feeds (%) — — 30.0 50.0 91.2 91.9ComorbiditiesDiabetes (%) 34.4 41.9 35.0 33.3 5.9 51.4End-stage liver disease (%) 4.4 19.4 0 0 0 16.2Chronic kidney disease (%) 22.2 22.6 20.0 16.7 12.8 16.2Cancer (%) 6.7 22.6 10.0 0.0 8.8 8.1Immunosuppression (%) 5.6 6.5 10.0 0.0 5.9 8.1Current smoker (%) 28.9 25.8 30.0 16.7 10.0 18.8*Race data missing for one individual in the sepsis survivor group.5 of 14
SC I ENCE ADVANCES | R E S EARCH ART I C L E0.21 to 0.98) for >3 days; Fig. 4B]. Levels of MTA in HAI-VAP had
prognostic power comparable to the commonly usedAPACHE II score,
calculated fromadozen physiological parameters,measured at the same
time points [AUC, 0.76 (95% CI, 0.58 to 0.94) for 0 to 1 day and 0.84
(95% CI, 0.68 to 1) for 2 to 3 days; Fig. 4C and fig. S2]. With a decision
boundary for classifying likely survivors versus nonsurvivors of 0.15 in
the 0- to 1-day interval,MTAhas a sensitivity of 0.75 and a specificity of
0.77. Because the metabolites in the HAI-VAP study were measured by
a different laboratory on a completely different set of sepsis patients
compared to the CAPSOD samples, this represents a highly stringentWang et al., Sci. Adv. 2017;3 : e1602096 8 March 2017formof biomarker replication.Our data demonstrate thatmeasurement
of a single metabolite, MTA, especially within 3 days of the onset of
suspected infection, can serve as a useful predictor of sepsis outcome
and that its accuracy was similar to that of APACHE II in the HAI-
VAP cohort.
Although MTA appears to be a good biomarker in isolation, we
tested whether the utility of MTA in predicting sepsis outcome could
be increased through the incorporation of clinical parameters that
would be available in a hospital setting. The relative importance of
MTAalongwith several other parameterswas evaluated using a supportA C
B
Fig. 2. High plasmaMTA levels are associatedwith sepsis death in ICU patients. (A) CAPSOD data show significantly higher MTA levels in sepsis nonsurvivors compared to
sepsis survivors. (B) Noninfectious SIRS individuals in the VAP cohort showno association betweenMTA and death at two timepoints. Day 0 is the time of the first blood draw; day
2 denotes that blood is drawn 2 days later. Early time points during sepsis for the HAI-VAP cohort (days 0 to 1 and days 2 to 3 of suspected infection) confirm significantly lower
MTA in sepsis survivors. Later time points (days >3) show no significant difference between sepsis survivors and sepsis nonsurvivors. (C) Hierarchical clustering of metabolites
(rows) with samples grouped by outcome (columns). MTA is clustered with two other metabolites in the methionine salvage pathway, SAM and SAH (refer to the diagram in
Fig. 1D). Peak areas were used for spermine, SAH, and SAM due to lack of internal standards, whereas all other metabolites were scaled to internal standards. The metabolites
are transformed into log2 values and then normalized to z scores. All P values were calculated by a two-tailed Mann-Whitney test.6 of 14
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Wang et al., Sci. Adv. 2017;3 : e1602096 8 March 2017vector machine implemented in the R caret package (37). We found
that, in the CAPSOD cohort, MTA was the variable of second highest
importance (Fig. 4D). If variable selection was instead performed on a
larger set of 10 clinical variables using the HAI-VAP study at the 0-
to 1-day time interval,MTAwas the variable of highest importance (Fig.
4D). Amodel incorporatingAPACHE II,MTA, and age developed using
theCAPSODdata showed robust cross-validationwith theCAPSODco-
hort (AUC, 0.81;median, 0.83; 95%CI, 0.59 to 0.96) (Fig. 4E). Thismodel
developed from the CAPSOD data performed well on the independent
HAI-VAP data set for days 0 to 1 (AUC, 0.77; 95% CI, 0.75 to 0.78)
(Fig. 4E). Similar results were observed at the 2- to 3-day time interval
(AUC, 0.82; 95% CI, 0.79 to 0.84; Fig. 4E). Thus, MTA alone had similar
prognostic ability compared to a model incorporating MTA with clinical
parameters.
MTA levels are correlated with high levels of
proinflammatory cytokines
On the basis of our previous studies indicating that exogenous MTA
could increase inflammation, as measured by pyroptosis in cultured
cells (25), we hypothesized that the prognostic ability of MTA could
be indicative of a harmful proinflammatory state. To test this possibility,
we determined whether MTA levels were correlated with levels of
proinflammatory cytokines. Early proinflammatory cytokines [IL-
1b and tumor necrosis factor–a (TNFa) (38)] were either largely un-
detected in our patient samples (IL-1b) or weakly correlated with
MTA (TNFa; Fig. 5A). However, both IL-6 and IL-8 showed significant
positive correlations with MTA levels in the sepsis patients but not in
the noninfectious SIRS patients (Fig. 5, B and C). Furthermore, mea-
surement of IL-6 and IL-8 each had significant prognostic power at this
early time point (0 to 1 day) used for cytokine measurement (for IL-6:
AUC, 0.85; 95%CI, 0.62 to 1.0; for IL-8: AUC, 0.81; 95%CI, 0.55 to 1.0;
fig. S3). As shown above, sepsis patients with elevated plasma MTA
have a worse prognosis, and these cytokine data indicate that the
elevated MTA levels may identify a subset of sepsis patients with a
hyperinflammatory state.Table 3. Summary of metabolite levels (at 0 to 1 day after suspected onset of infection) and association with death in sepsis and in NI-SIRS patients. All
calculations were based on log2(x + 1) transformations of either ratios of metabolite to internal standards or metabolite peak areas (for SAM, SAH, and
spermine). P values were calculated by two-tailed Wilcoxon rank-sum test.MetaboliteVAP sepsis VAP NI-SIRSSepsis survivors
(mean ± SD)Sepsis nonsurvivors
(mean ± SD)P
NI-SIRS survivors
(mean ± SD)NI-SIRS nonsurvivors
(mean ± SD)PMTA 0.24 ± 0.17 0.38 ± 0.28 0.03 0.25 ± 0.14 0.24 ± 0.07 0.93SAM 12.72 ± 0.90 13.50 ± 1.16 0.06 12.94 ± 0.97 13.00 ± 0.78 1SAH 11.28 ± 1.09 12.10 ± 1.27 0.05 11.43 ± 1.25 11.81 ± 0.94 0.46Methionine 0.22 ± 0.07 0.37 ± 0.45 0.75 0.24 ± 0.10 0.20 ± 0.12 0.46Phe 0.81 ± 0.11 0.82 ± 0.19 0.78 0.78 ± 0.16 0.76 ± 0.17 0.93Ile 0.54 ± 0.20 0.53 ± 0.30 0.85 0.54 ± 0.24 0.51 ± 0.26 0.42Leu 0.74 ± 0.22 0.71 ± 0.33 0.56 0.71 ± 0.24 0.70 ± 0.33 0.74Arg 0.63 ± 0.19 0.60 ± 0.29 0.40 0.58 ± 0.25 0.63 ± 0.23 0.79Spermine 14.26 ± 1.10 14.19 ± 1.95 0.31 13.43 ± 1.17 13.34 ± 0.69 0.93Fig. 3. Mouse NTS infection transiently increases MTA levels in plasma but
decreases levels in the spleen. (A) Survival curve for mice injected with 1 × 106S. Typhimurium by the intraperitoneal route. Most of the mice die by 2 days. (B) Mouse
plasma MTA levels for uninfected mice and mice at 6 and 24 hours after infection.
(C) Mouse spleen MTA levels for uninfected mice and mice at 6 and 24 hours after
infection. (D) Mouse liver MTA levels for uninfected mice and mice at 6 and 24 hours
after infection. For each time point, means ± SEM are from 10 mice, except for 4 mice
for liver, and P values are from t test.7 of 14
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of mice
Connecting the methionine salvage pathway to sepsis through associa-
tion of both genetic differences in the pathway and the metabolite they
regulate led us to hypothesize that MTA might not only serve as a bio-
marker but could alsomodulate the course of infection.We determined
whether survival of mice would be affected by administering exogenous
MTA in the NTS challengemodel. Mice were injected withMTA either
30 min before infection or 6 hours after infection. MTA administered
before infection prolonged survival (P= 0.01; Fig. 6A). This is consistent
with elevated MTA before infection having a protective effect against
NTS bacteremia, and we hypothesize that beneficially elevated MTA
could occur either through exogenous administration or through a ge-
netic difference that reduces expression of APIP. In contrast, when
administered 6 hours after infection (concomitant with the natural
peak in plasma MTA; see Fig. 3), no protective effect was seen (P =
0.45; Fig. 6B).
To examine the mechanism of prolonged survival with early adminis-
tration ofMTA, wemeasured levels of proinflammatory cytokines (TNFa
and IL-6). TNFa and IL-6 were both induced in plasma relative to un-
infected mice, but the level of induction was suppressed in the MTA-
pretreatedmice (P = 0.01 for TNFa and P = 0.03 for IL-6; Fig. 6C). This
difference is not secondary to differences in bacterial load because bac-
terial colony-forming units (CFUs) were similar (P = 0.90; fig. S4). Al-Wang et al., Sci. Adv. 2017;3 : e1602096 8 March 2017though the patient data demonstrate that elevated plasmaMTA during
infection is a biomarker of a hyperinflammatory state, exogenousMTA
suppresses inflammatory cytokine levels during NTS infection in mice.DISCUSSION
As of 2010, 170 biomarkers had been evaluated for use in sepsis (39),
including gene expression, proteins, andmetabolites, but only a handful
have been adopted for clinical use. It is increasingly popular to take a
completely agnostic approach in identification of biomarkers and use
machine learning to deconvolute omics data sets into biomarker panels
for the particular application (40). The approach demonstrated here in-
tegrates genotype, cytokine, and metabolite data with testing in an
animal model to reveal a robust biomarker that, at least in mice, can
be added exogenously to affect the course of infection. Genotype mar-
kers are unique in that they are unaffected during the course of the dis-
ease (except in the context of cancer), and therefore, the direction of
causation from genotype to disease is unambiguous. However, as the
last decade of GWAS has demonstrated, effect sizes of most associated
common genetic variants are small (41). Biomarkers based on gene ex-
pression have increased in popularity, and some are in clinical use, par-
ticularly in oncology (42, 43). However, the exquisite regulation of gene
expressionmeans that it can serve a causal role in disease, but dysfunctional
expression can also be a consequence of disease. Other molecularFig. 4. EvaluationofMTAas abiomarker for sepsis survival. (A) ROC curves forMTA andAPACHE II from theCAPSODcohort. (B) ROC curves forMTA from theHAI-VAP cohort
at days 0 to 1 anddays 2 to 3. (C) ROC curve for APACHE II fromHAI-VAP at enrollment. (D) Ranked variable importance for the CAPSODcohort and theHAI-VAP cohort at days 0 to
1 for prognosis of death. MTA ranks as the second most important variable among all six clinical parameters in the CAPSOD cohort and the most important among 10 clinical
parameters in the HAI-VAP cohort. (E) Distribution of AUC values for cross-validation with CAPSOD or with the independent HAI-VAP data set using an SVM approach. The SVM
modelwas constructedusing theCAPSODcohortwith the threemost important variables (APACHE II,MTA, andage). Testingof themodelwas carried out usingCAPSODfor cross-
validation and independent testing with two time points of the HAI-VAP cohort at days 0 to 1 and days 2 to 3 (50 iterations were run for each data set).8 of 14
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effectors of the physiological process being studied. Our work demon-
strates that combiningmeasurement of biomolecules with genetic asso-
ciation studies allows for the identification of biomarkers that are not
only symptoms but also likely regulators of disease physiology.
Here, we startedwith a genetic biomarker of bacteremia and death in
a SIRS cohort and validated the SNP association and implicated the en-
tire methionine salvage pathway in a separate NTS bacteremia data
set. We then evaluated the metabolite regulated by this pathway in
two different patient cohorts. Therefore, both the genetic association
and the metabolite association with sepsis outcome have now been
observed in two independent patient populations and under a variety
of sepsis conditions.
Closer examination of the details of these studies also demonstrates
the advantages and limitations of genetic and metabolite biomarkers.
Our initial discovery that the SNP in APIP (rs514182) was associated
with bacteremia came from a study that used a cohort of nearly a thou-
sand subjects and revealed an OR of 2.0 (25). The OR in the NTS data
set of nearly 3000 subjects was quite similar [OR, 2.3 (for rs2433162)
and 1.4 (for rs514182)]. In contrast, the OR for sepsis death usingWang et al., Sci. Adv. 2017;3 : e1602096 8 March 2017MTA is 7.18 from the HAI-VAP study of 62 patients, indicating that
the odds of death are increased 7.18-fold when MTA concentration is
doubled. Although ORs for genotypes are not entirely comparable to
the OR of a continuous variable, the significant association from such
a vastly smaller group of patients underscores the robustness and large
effect of the MTA metabolite biomarker. Our work demonstrates the
advantage in combining genetic association studies for causal inference
with metabolite association studies of larger effect size and possibly
greater clinical utility.
MTA could be a valuable biomarker not only for prognosis but also
in determiningwhether patients could benefit from therapies that either
enhance or suppress the immune system. An emerging view is that sep-
sis immunomodulatory therapies have failed in clinical trials because
different subpopulations benefit from either increasing or suppressing
inflammation (44). Specifically, sepsis patients early in their course
might benefit from therapies that reduce the action of proinflammatory
cytokines. Conversely, patients later in the course of their infection often
have an immunosuppressed state thatmight benefit from therapies that
enhance immune function. The timing of elevated plasma MTA (and
decreased tissue MTA) suggests that it represents an acute response to
bacterial infection. Our data support the idea that elevated MTA levels,
which are prognostic of later death, are indicative of an excessive im-
mune response. IL-6 and IL-8 levels are correlated with MTA levels in
sepsis patients, indicating that MTA levels could be a marker of “cyto-
kine storm.” However, MTA administered before infection suppresses
inflammatory cytokine production in mice and prolongs survival. This
suppression of inflammation was surprising given our previous studies
demonstrating increased pyroptosis with MTA in lymphoblastoid cell
lines and macrophages, but it is consistent with studies that have de-
monstrated that MTA protects against LPS endotoxemia (29) and
can reprogram macrophages to have reduced TNFa production (45).
Together, the human and mouse data suggest that MTA could serve
not only as a prognostic biomarker for identification of patients in need
ofmore aggressive care but also as a predictive one for identifyingwhich
patients would benefit from immunosuppressive therapies, including
MTA itself. Notably,MTA remains elevated longer (at least up to 3 days
in our data) compared to the cytokines themselves, which have a much
more transient increase and may start declining rapidly within the first
24 hours of infection (46). The more prolonged elevation of MTAmay
enhance its clinical utility.
An additional level of complexity in understanding the utility and
biological effects of MTA comes from variation in intracellular versus
extracellular levels. We propose that steady-state intracellular levels of
MTA are regulated by genetic variation in the methionine salvage and
polyamine synthesis pathways.With acute infection, there is an increase
in plasma MTA with a decrease seen in tissues. This decrease in intra-
cellular MTA is likely not mediated by an increased flux through the
pathway because the product of the pathway, methionine, was not ob-
served to increase as MTA decreased; rather, we observed a decrease of
methionine to 56% of uninfected levels in the spleens of mice at 6 hours
after infectionwith Salmonella.We speculate that high levels ofMTA in
patients might be released from cells as part of the host response to
suppress and resolve inflammation. One possible model reconciling
our genetic, metabolite, and mouse data shows that high intracellular
levels before infection (due to APIP genotype) are protective, possibly
because the cells aremore susceptible and poised to undergo pyroptosis.
However, if the infection is not effectively resolved, the patient’s course
worsens, leading to further release ofMTA (possibly through pyroptosis,
another form of cell death, or an unknownmechanism) that is indicativeVAP sepsis (days 0−1)
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Fig. 5. Correlation of MTA and plasma levels of proinflammatory cytokines in
the HAI-VAP cohort. (A) MTA is not correlated with plasma levels of TNFa for both
VAP sepsis and NI-SIRS patients at days 0 to 1. (B) MTA is significantly correlated with
plasma levels of IL-6 inHAI-VAP sepsis patients at days 0 to 1but not inNI-SIRS patients.
(C) MTA is significantly correlated with plasma levels of IL-8 in HAI-VAP sepsis patients
at days 0 to 1 but not in NI-SIRS patients.9 of 14
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study demonstrates that MTA timing, localization, and regulation are
complex, and MTA levels not only are regulated by genetic differ-
ences but also change dynamically during the course of infection.
Although the mouse data demonstrate an inverse relationship of
MTA levels in tissues and plasma, future studies are required to verify
that this relationship holds in humans and is associated with sepsis out-
come. Furthermore, whereas the experiments with exogenous MTA
demonstrate that lethal NTS infection and cytokine levels in mice can
be modulated by MTA, whether endogenous MTA definitively plays
this role during infection and themechanismof its immunemodulation
will require genetic loss-of-function experiments in mice (likely in a cell
type–specific manner) with more detailed phenotyping.
Future studies aimed at moving MTA into the clinic will need to
incorporate accurate absolute quantification of MTA in a clinical labo-
ratory platform that is more common than liquid chromatography–
mass spectrometry. In addition, it will be crucial to further examine
the utility, dosing, pharmacodynamics, and mechanism of modulating
MTA levels to suppress inflammation in animal models and, if results
are promising, to validate in patients. The goal is to ultimately help the
more than 1 million patients hospitalized with sepsis in the United
States every year (47) and the millions more throughout the world.Wang et al., Sci. Adv. 2017;3 : e1602096 8 March 2017MATERIALS AND METHODS
GWAS populations
Ethical approval for the study was obtained from the Kenya Medical
Research Institute National Scientific Steering and Research Commit-
tees and theOxford Tropical Research Ethics Committee. Following ex-
planation of the study, written informed consent was obtained from the
parent or guardian of each child included in the study. Children (under
13 years of age) presenting with bacteremia to Kilifi District Hospital,
Kenya, between 1 August 1998 and 30 October 2010 were recruited to
the Wellcome Trust Case Control Consortium 2 (WTCCC2) study of
bacteremia, as described elsewhere (48). Briefly, blood samples for bac-
terial culture (BACTEC9050, BectonDickinson)were taken from every
child admitted to the hospital during the study period, with the excep-
tion of elective surgical admissions and children admitted followingmi-
nor accidents. Control samples were collected as part of a birth cohort
study from consecutive births between 1 May 2006 and 30 April 2008,
among the same population as the case samples in the Kilifi district.
GWAS analysis
Genome-wide genotyping (Affymetrix SNP 6.0 chip) was performed
for samples from 218 cases of NTS bacteremia and 3000 controls.
Followingwhole-genome imputation andquality control (31), 180 casesFig. 6. Exogenous MTA prolongs survival and suppresses proinflammatory cytokines. (A) MTA injection 30 min before S. Typhimurium infection (1 × 106 CFUs by
intraperitoneal injection) prolongs survival. Data were compared by log-rank test (P = 0.012; hazard ratio, 2.1) with n = 17 in each group, combined from three different
experiments that each showed the same trend. (B) MTA injection 6 hours after S. Typhimurium infection does not prolong survival. Data were compared by log-rank
test (P = 0.45; hazard ratio, 0.82) with n = 18 in each group combined from three different experiments. (C) Salmonella-induced cytokine levels are decreased with MTA
before treatment. MTA was administered 30 min before S. Typhimurium injection. Plasma was collected at 3 hours after infection and measured by enzyme-linked
immunosorbent assay (ELISA). n = 20 for each infected condition measured over three experiments and n = 4 for uninfected controls. Median and interquartile range
are shown in red. For TNFa, values were compared by the Mann-Whitney test [P = 0.01; median of 21.1 pg/ml for dimethyl sulfoxide (DMSO) + Salmonella and median
below limit of detection for MTA + Salmonella; means of 25.3 pg/ml for DMSO + Salmonella and 14.3 pg/ml for MTA + Salmonella]. For IL-6, log transformation resulted in
normal distributions that were compared by unpaired t test (P = 0.03; medians of 1134 pg/ml for DMSO + Salmonella and 831 pg/ml for MTA + Salmonella; means of 4604 pg/ml
for DMSO + Salmonella and 1242 pg/ml for MTA + Salmonella).10 of 14
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ysis. Genome-wide association analysis was performed under additive
and genotypicmodels of association with SNPTEST2 (49), with the first
four principal components of genome-wide genotyping data included
in the models to account for the underlying population structure. SNPs
with minor allele frequencies >0.05 (additive model; >0.1, genotypic
model), with imputation info scores >0.8, and without evidence for de-
parture fromHardy-Weinberg equilibrium (P < 1 × 10−10) were included
in the analysis (7,950,619 SNPs, additivemodel; 4,669,669 SNPs, genotypic
model). Genotype data for Kenyan GWAS samples will be made avail-
able via the European Genome-phenome Archive (EGAS00001001756).
Pathway enrichment analysis of NTS GWAS
To test for the enrichment of biologically related genes at NTS-associated
loci, we used INRICH (33).We defined NTS-associated regions in PLINK
(50), as nonoverlapping genomic regions containing an NTS-associated
SNP (P < 1 × 10−5 in either an additive or a genotypic model), bounded
in the 3′ and 5′ directions by the extent of linkage disequilibrium (r2 > 0.2)
to themost-associated SNP.We identified 73 independentNTS-associated
genomic regions, which we tested for enrichment in 1320 gene sets in
the curated canonical pathway gene set in GSEA (Gene Set Enrichment
Analysis) (51). Empirical P values for enrichment were calculated with
100,000 replicates, and multiple-testing correction of P values was per-
formed with 10,000 bootstraps.
Metabolite study populations and clinical data collection
For the CAPSOD cohort, informed consent was obtained, and 1152 pa-
tients who met at least two SIRS criteria and had suspected infection
were enrolled prospectively from emergency departments at three ur-
ban, tertiary care centers (29). Demographic and clinical data as well as
venous plasma and whole blood were collected at time of enrollment
and 24 hours later. Clinical adjudication for clear presence of infection
and the etiologic infectious agent was performed by a board-certified
clinician. Survival at 28 days was determined.
The HAI-VAP study was approved by the Institutional Review
Board of the Duke University Medical Center, the Durham Veterans
Affairs Medical Center, and UNCHealth Care. This prospective obser-
vational cohort study targeted patients who were at high risk of devel-
oping VAP by virtue of recent intubation and an expected duration of
ventilation of greater than 48 hours. Enrollment occurred from the
emergency department, intensive care units, step-down units, and other
appropriate locations within the Duke University Health System. The
study was also conducted at the Durham Veterans Affairs Medical
Center and UNC Health Care. Clinical information and biological
samples were collected daily through day 6. If no VAP or other HAI
occurred, sample collection ended at day 6, and this patient served as
an uninfected control. However, if an HAI occurred within this
window, postinfection samples were collected every other day for an
additional week. Survival status was determined at day 30. An adjudi-
cation committee of physicians used all prospectively collected clinical
data to categorize patients into specific HAI groups, incorporating clin-
ical, microbiological, and radiographic data.
Patients were grouped as sepsis survivors, sepsis nonsurvivors, non-
infection survivors, and noninfection nonsurvivors. APACHE II scores
were calculated for time of enrollment. Plasma samples were used for
metabolite profiling, and whole blood was used for transcriptome se-
quencing, as described below. For the study presented here, 62 patients
were included, and 157 samples from those patients were subjected to
further measurement and analysis.Wang et al., Sci. Adv. 2017;3 : e1602096 8 March 2017Metabolite profiling
Semiquantitative metabolomics analysis for the CAPSOD samples was
previously described (34). The metabolite profiling of the HAI-VAP
samples was performed by the Duke Proteomics and Metabolomics
Shared Resource. A method was developed for the measurement of
10 metabolites (leucine, isoleucine, spermidine, methionine, phenyl-
alanine, spermine, arginine, MTA, SAM, and SAH) in human plasma
samples. A total of 157 human plasma samples were block-randomized
before sample submission based on outcomes to reduce any batch
effects. After thawing, all samples were vortexed briefly and centrifuged
at 1700 rpm for 10 min. Then, 100 ml of each sample was pipetted di-
rectly into a 96-well, 1-ml Eppendorf plate. For each sample well, 900 ml
of methanol/0.1% formic acid containing internal standards was added.
The plate was capped and allowed tomix at 650 rpmat 25°C for 30min.
The platewas then centrifuged for 10min at 3000 rpm. The supernatant
(400 ml) from eachwell was transferred to another 96-well plate, and the
extracts were dried under a gentle stream of nitrogen. Samples were re-
constituted in 32 ml of 50:49:1 acetonitrile/water/trifluoroacetic acid
(TFA) and mixed at 650 rpm for 5 min, and then 128 ml of 1% TFA
in water was added. Quality control was monitored by a pooled sample
injected several times before the start of the run queue, once after every
20 sample runs, and once at the end to measure the performance of the
assay during sample analysis.
Liquid chromatography separation of these 10 polarmetabolites was
performed on a Waters Acquity UPLC (Milford) using a Waters Ac-
quity 2.1-mm×10-mm, 1.7-mmBEHC18 column, followedby introduc-
tion into a Xevo TQ-S mass spectrometer (Waters) using electrospray
ionization operating in multiple reaction monitoring (MRM) mode.
MRM transitions (compound-specific precursor to product ion transi-
tions) for each analyte and internal standard were collected over the ap-
propriate retention time. The total run time per injection was 17.5 min.
The datawere imported into Skyline software (https://skyline.ms/project/
home/software/Skyline/begin.view) for peak integration and exported
into Excel for ratio calculation of analyte to internal standard, where
applicable. Note that because all spermidine data were below the limit
of quantitation in all plasma samples, there are no data present for this
analyte.
The mouse plasma samples were prepared in the same manner as
the human plasma samples, except for the fact that formic acid was left
out of themethanol extraction after it was determined tomore efficient-
ly extract MTA. For the mouse spleens, phosphate-buffered saline
(PBS) was added to each at 1 ml per 100 mg of wet weight. Samples
were then probe-sonicated at power level 3 for three bursts of 5 s each,
cooling on ice between bursts. Bradford assay was performed on each
solubilized tissue extract using 10-fold diluted material. Samples
corresponding to 575 mg of total protein from each tissue were taken
out and normalized to 100 ml in total with PBS in a 96-well plate.
Samples were then processed as above with 900 ml of methanol.
Mouse infections
Mouse studies were approved by the Duke Institutional Animal
Care and Use Committee and adhere to the Guide for the Care and
Use of Laboratory Animals of the National Institutes of Health (NIH).
S. Typhimurium (14028s + p67GFP) were grown overnight in LBmedia +
ampicillin. Bacteria were diluted 1:33 and grown for an additional
2 hours and 40 min. Bacteria were washed and resuspended in PBS.
Mice (age/sex-matched in each experiment; 9 to 14 weeks old) were
injected with 1 × 106 bacteria by the intraperitoneal route. Following 6 or
24 hours, mice were euthanized, and blood collected by cardiac puncture11 of 14
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mice were harvested at 0 hours. Plasma from blood samples was collected
usingMicrotainer plasma separator tubes with lithium heparin (Becton
Dickinson) and stored at −80°C until ready for analysis. Spleens were
weighed and stored at −80°C until analysis. For survival curves, mice
were assessed using a morbidity scale twice daily. MTA injections were
given intraperitoneally (96 mg/kg body weight, dissolved in DMSO)
either 30 min before or 6 hours after Salmonella infection. TNFa and
IL-6 levels were measured by ELISA according to the manufacturer’s
instructions (R&D Systems).
Statistical analysis
All samples were binned into four time points according to days rela-
tive to onset of infection. The four time points used in this study are
the following: before onset of infection, days 0 to 1 of infection, days 2
to 3 after infection, and days 4 to 9 after infection. For some time
points, MTA levels were measured for multiple times from the same
patient, and they were averaged for the subsequent analyses.
Before the statistical analyses, metabolite ratios (metabolite peak area
over the internal standard) were rescaled via the log2(x + 1) trans-
formation. Wilcoxon rank-sum test was used to detect the significance
of differential levels among groups (sepsis versus noninfectious SIRS
and survivors versus nonsurvivors) at different time points, as well as
the correlation of outcome and clinical demographic parameters. Kruskal-
Wallis testwas performed for samples at different timepoints and among
groups. Ward’s hierarchical clustering of Pearson product-moment
correlations was used to group different metabolites and patients.
To evaluate the sensitivity and specificity ofMTA as a biomarker for
sepsis risk, we used amachine learningmethod, the SupportVectorMa-
chine (SVM), implemented in the R caret package version 6.0-58 using
default parameters (37). Briefly, the SVM algorithm was used to calcu-
late the importance of all variables and rank them. The top three varia-
bles were then selected to classify the samples into sepsis survivors and
nonsurvivors. The CAPSOD study was used as the discovery panel and
to construct the optimized prediction model, and then the HAI-VAP
study served as an independent data set to test themodel. Eighty percent
of the CAPSOD data set served as the training data set for model
building, and the remaining 20% served as the testing data set. Cross-
validation was applied on both the CAPSOD data and the independent
HAI-VAP data set to evaluate the accuracy and specificity of prediction
performance for 50 iterations. ROC curves and AUC values were
calculated using the R pROC package version 1.8 (52). All statistical
analyses and modeling were performed with the R program (53).SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/3/3/e1602096/DC1
fig. S1. MTA levels in noninfectious SIRS versus sepsis patients in the HAI-VAP study.
fig. S2. ROC curves for APACHE II from HAI-VAP (on days 2 to 3).
fig. S3. ROC curves for IL-6 and IL-8 from HAI-VAP (on days 0 to 1).
fig. S4. Salmonella spleen CFUs are not altered by MTA at the time of cytokine measurement
(3 hours).
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